Journals / Göztepe Tıp Dergisi / 2011 / Cilt: 26 - Sayı: 1

Metabolic disturbances arising out pharmacotherapies of bipolar disorder: the role of carnitine deficiency? case report

Bipolar bozukluk farmakoterapisi ile gelişen metabolik bozukluklar: karnitin eksikliğinin rolü?

Pages
33–38
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Blood sugar, HbA1c and HOM levels improved at treatment period and reached to normal levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, metabolic disturbances developed in a 60 years old female patient having bipolar disorder whose treatment has been going on and treatment approaches were outlined.
📊
Key Findings & Data:There was a sharp increase in her weight (+5 kg) after adding olanzapine 2.5 months before who has still been taking sodium (Na) valproate treatment.
💡
Conclusion & Impact:Blood sugar, HbA1c and HOM levels improved at treatment period and reached to normal levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, metabolic disturbances developed in a 60 years old female patient having bipolar disorder whose treatment has been going on and treatment approaches were outlined. There was a sharp increase in her weight (+5 kg) after adding olanzapine 2.5 months before who has still been taking sodium (Na) valproate treatment. But, she failed to accordance with diet and to loose weight because of carbohydrate craving, night eatings and low activity level. Than she gave up dieting. After 2.5 years from the first consult, she applied to dietitian again to loose weight. This time, her weight was 100 kg (+17.5 kg), and in biochemical tests, glucose, HbA1c and homocystein levels were higher than reference values, but zinc and copper levels were lower. According to endocrinologic evaluation IGT was detected with OGTT and so metformin was added to treatment and quetiapine replaced to antipsychotic olanzapine. Determined body fat percent at second consult (% 52.9) was too higher than expected (% 35.0). It was thought that carnitine deficiency might be the cause. So, L-carnitine (1 mg/day) was added to treatment. Our patient, whose follow up period has been going on loosed % 13.3 of her weight and % 7.7 of her body fat than values determined at the beginning. Blood sugar, HbA1c and HOM levels improved at treatment period and reached to normal levels.

Özet

Bu çalışmada, İÜ. CTF. Psikiyatri Polikliniği’nde Bipolar Bozukluk tanısı koyularak uygun ilaç tedavisine başlanan 60 yaşındaki kadın hastada gelişen metabolik bozukluklar ve yapılan tedavi yaklaşımları irdelenmiştir. Hastamızın 4 yıldan bu yana kullanmakta olduğu sodyum (Na) valproat tedavisine 2.5 ay önce olanzapine eklenmesiyle vücut ağırlığında 5 kg’lık ani artış olur. Ancak, şiddetli tatlı yeme isteği, gece yemeleri ve aktivite azlığı nedenleri ile diyete uymada ve kilo vermede başarısız olur ve kendiliğinden diyet tedavisini bırakır. Hastamız, ilk başvurusundan yaklaşık 2.5 yıl kadar sonra zayıflamak için tekrar diyetisyene başvurduğunda, ağırlığında 17.5 kg artış olduğu, biyokimyasal testlerden glukoz, HbA1c, homosistein düzeylerinin referans değerlerden daha yüksek; çinko ve bakır düzeylerinin ise daha düşük olduğu bulunmuştur. Yapılan endokrin değerlendirme sonucunda OGGT ile IGT saptanarak tedaviye metformin eklenmiş ve antipsikotik olanzapin yerine quetiapine başlanmıştır. Düşük kalorili uygun diyetle birlikte aktivite artışı önerilmiştir. Hastamızın vücut analizinde saptanan yağ oranının (% 52.9), beklenilenin (% 35.0) çok üzerinde olması nedeniyle karnitin eksikliği gelişmiş olabileceği düşünülerek tedaviye L-carnitine (1 g/gün) eklenmiştir. Halen kontrolleri devam etmekte olan hastamız başlangıca göre ağırlığının % 13.3’ünü kaybetmiş, vücut yağı ise % 7.7 azalmıştır. Başlangıca göre kan şekeri, HbA1C ve HOM düzeyleri tedavi sürecinde iyileşme göstererek normal sınırlara ulaşmıştır.

🔖

Cite This Article

Özenoğlu, A., UĞURLU, S., EKER, E. (2022). Metabolic disturbances arising out pharmacotherapies of bipolar disorder: the role of carnitine deficiency? case report. Göztepe Tıp Dergisi, Cilt: 26 - Sayı: 1, 33–38. https://ajindex.com/articles/526132

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Özenoğlu A. Psikiyatrik hastalıkların tedavisi süresince iştah ve vücut ağırlığında oluşan değişiklikler ve çözümüne yönelik yaklaşımlar. Diabet Bilimi 2006;4:34-50
  2. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 2001;62:22-31. PMid:11346192 3. Blin O, Micallef J. Antipsychotic associated weight gain and clinical outcome parameters. Journal of Clinical Psychiatry 2001;62:11-13. PMid:11346191 4. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying druginduced weight gain in psychiatric patients. Journal of Psychiatric Research 2003;37:193-220.
  3. Haupt DW, Newcomer JW. Abnormailities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002;53:925-33.
  4. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337- 45. http://dx.doi.org/10.1001/archpsyc.59.4.337 PMid:11926934 7. Allison DB, Mentore JL, Heo M, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96. PMid:10553730 8. Susman N, Ginsberg D. Effect of psychotropic drugs on weight. Psychiatric Ann 1999;29:580-94
  5. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-2. PMid:10408570 10. Pylvanen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in Valproate-associated obesity. Epilepsia 2002;43:514-517.
  6. Özenoğlu A, Can G, Hatemi H. Yetişkin kadın ve erkeklerde vücut kompozisyonu referans değerleri. Endokrinolojide Yönelişler 2001;10:58-63
  7. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(Suppl 23):30-8. PMid:11603883 13. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;17:3
  8. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antypsychotic drugs. Am J Psychiatry 1999;156:312-14. PMid:9989571 15. Virk S, Schwartz TL, Jindal S, et al. Psychiatric medication induced obesity: an aetiologic review. O